Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Share Class Description:
EW: Ordinary SharesTotal Employee Number:
16,000Compare
Compare
Traded in other countries / regions
EW.USAEW.MexicoEWL.GermanyE1WL34.BrazilEWLS.Austria1EW.ItalyEW.Switzerland0REN.UK Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
2000-04-03Description
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.22 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.45 | |||||
Interest Coverage | 85.34 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 13.29 | |||||
Beneish M-Score | -2.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.1 | |||||
3-Year EBITDA Growth Rate | -2.7 | |||||
3-Year EPS without NRI Growth Rate | 1.1 | |||||
3-Year FCF Growth Rate | 14.3 | |||||
3-Year Book Growth Rate | 23.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.29 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.05 | |||||
9-Day RSI | 68.71 | |||||
14-Day RSI | 64.63 | |||||
3-1 Month Momentum % | 7.98 | |||||
6-1 Month Momentum % | 1.43 | |||||
12-1 Month Momentum % | 10.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.42 | |||||
Quick Ratio | 3.63 | |||||
Cash Ratio | 2.61 | |||||
Days Inventory | 295.19 | |||||
Days Sales Outstanding | 40.47 | |||||
Days Payable | 47.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 2 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.87 | |||||
Operating Margin % | 27.62 | |||||
Net Margin % | 17.34 | |||||
EBITDA Margin % | 24.73 | |||||
FCF Margin % | 17.28 | |||||
OCF Margin % | 21.55 | |||||
ROE % | 10.6 | |||||
ROA % | 8.18 | |||||
ROIC % | 17.12 | |||||
3-Year ROIIC % | 0.88 | |||||
ROC (Joel Greenblatt) % | 52.6 | |||||
ROCE % | 11.81 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 47.86 | |||||
Forward PE Ratio | 30.08 | |||||
PE Ratio without NRI | 33.5 | |||||
Shiller PE Ratio | 35.61 | |||||
Price-to-Owner-Earnings | 70.79 | |||||
PEG Ratio | 5.98 | |||||
PS Ratio | 8.35 | |||||
PB Ratio | 5.05 | |||||
Price-to-Tangible-Book | 7.17 | |||||
Price-to-Free-Cash-Flow | 48.54 | |||||
Price-to-Operating-Cash-Flow | 38.94 | |||||
EV-to-EBIT | 35.13 | |||||
EV-to-Forward-EBIT | 30.33 | |||||
EV-to-EBITDA | 31.51 | |||||
EV-to-Forward-EBITDA | 25.18 | |||||
EV-to-Revenue | 7.79 | |||||
EV-to-Forward-Revenue | 7.36 | |||||
EV-to-FCF | 45.08 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Projected-FCF | 2.85 | |||||
Price-to-DCF (Earnings Based) | 1.77 | |||||
Price-to-DCF (FCF Based) | 4.21 | |||||
Price-to-Median-PS-Value | 0.87 | |||||
Price-to-Graham-Number | 3.27 | |||||
| Price-to-Net-Current-Asset-Value | 16.12 | |||||
| Price-to-Net-Cash | 77.32 | |||||
Earnings Yield (Greenblatt) % | 2.85 | |||||
FCF Yield % | 2.09 | |||||
Forward Rate of Return (Yacktman) % | 5.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:EW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edwards Lifesciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6,303.5 | ||
| EPS (TTM) ($) | 1.89 | ||
| Beta | 0.9173 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.06 | ||
| Volatility % | 15.78 | ||
| 14-Day RSI | 64.63 | ||
| 14-Day ATR ($) | 2.470576 | ||
| 20-Day SMA ($) | 87.427 | ||
| 12-1 Month Momentum % | 10.56 | ||
| 52-Week Range ($) | 72.3 - 92.88 | ||
| Shares Outstanding (Mil) | 575.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edwards Lifesciences Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 17:00 | In 122 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 17:00 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 23 days | ||
| Guidance call for 2026 | 2026-05-12 15:40 | 77.17 (-3.21%) | ||
| General meeting for 2026 | 2026-05-07 10:00 | 83.20 (+0.57%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 17:00 | 81.53 (+1.73%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 81.53 (+1.73%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 10:00 | 85.78 (+2.13%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 10:00 | 84.26 (+4.19%) |
Show
Entries
Edwards Lifesciences Corp Frequently Asked Questions
What is Edwards Lifesciences Corp(EW)'s stock price today?
The current price of EW is $90.46. The 52 week high of EW is $92.88 and 52 week low is $72.30.
When is next earnings date of Edwards Lifesciences Corp(EW)?
The next earnings date of Edwards Lifesciences Corp(EW) is 2026-07-24 Est..
Does Edwards Lifesciences Corp(EW) pay dividends? If so, how much?
Edwards Lifesciences Corp(EW) does not pay dividend.
Guru Commentaries on NYSE:EW
Press Release
Articles on Edwards Lifesciences Corp
No articles.
Headlines
See More- 1
Jun 16, 2026
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device
Benzinga • 12:52pm
Edwards Lifesciences hits 52-week high after Medicare coverage proposal
Seeking Alpha • 12:16pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers